Novo Nordisk (China) Pharmaceuticals Co., Ltd. (the “Company”) is committed to provide high quality drugs and devices to patients and to safeguard patient safety. Recently the company was contacted by a few patients stating that the NovoPen® 4 (an insulin delivery device) they had bought from local pharmacies could not be used as normal after several times of use. Following an investigation, Novo Nordisk has identified that these devices are not produced by the company but are counterfeit NovoPen® 4. Novo Nordisk has reported these incidents of counterfeit NovoPen® 4 to the local regulatory authorities, and an investigation has subsequently been carried out by the relevant related local authority.
The counterfeit NovoPen®4 has a risk of delivering a too low amount of insulin which can cause an elevated blood glucose level and affect the treatment of the disease. To avoid buying the counterfeit NovoPen®4, the company hereby provides the below information in order to assist patients to distinguish genuine NovoPen®4 from the counterfeit. Meanwhile, the company reminds the customers to buy NovoPen®4 from the normal hospitals or pharmacies, instead of from an illegal source.
Should any products be suspected of being counterfeit after comparison with the above information, we highly recommend you immediately contact your local regulatory authorities.
Novo Nordisk is committed to combat counterfeit products and work closely together with authorities to safeguard the health of patients.